Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to show that the SPECT/CT whole body recording procedure lasting less than or equal to 30 minutes in a VERITON-CT™ camera, can be substituted for the classic procedure, giving at least equivalent information in searches for primary or metastatic neoplastic lesions.
Patients with thyroid cancer treated with iodine 131 will receive an iodine 131 activity of between 1100 and 3700 MBq delivered as a capsule orally to eliminate the remaining thyroid tissue. Hormone replacement therapy (HRT) is then started to correct the hypothyroidism.
3 days later, a 2D whole body recording will be associated with complementary Single Photonic Emission Computed Tomography CT scans (SPECT/CT). It enables visualising the fixation of iodine 131, provides information on the thyroid remnants left in place during surgical thyroidectomy and to carry out an extension assessment by visualizing the possible presence of metastases fixing iodine at the level of the regional lymph nodes or many distant sites, in particular, lung and bone.
In VERICATH study, the hypothesis is that this classic procedure could be advantageously replaced by a single full-body SPECT/CT recording of a limited duration (≤ 30 minutes), obtained with a camera state-of-the-art semiconductor device called the VERITON-CT™ (Spectrum Dynamics Medical) camera.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Person suffering from thyroid cancer and treated by iodine 131 (1100 MBq or 3700 MBq) | Experimental | The study will be offered to patients suffering from thyroid cancer and treated by iodine 131 (1100 MBq or 3700 MBq). When they come in nuclear medicine to have the iodine scan in Anger's camera, if they signed the consent, they will the SPECT/CT whole body in VERITON-CT camera |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| A SPECT-CT whole body is added in VERITON-CT camera | Other | A SPECT-CT whole body in VERITON-CT camera is added after the conventional procedure recorded in Anger camera |
|
| Measure | Description | Time Frame |
|---|---|---|
| Compare post-therapy imaging performed with the two procedures | Type of lesions
| 18 months |
| Measure | Description | Time Frame |
|---|---|---|
| Compare the two procedures in terms of cancer status result. | Status of cancer | 18 months |
| Determine the feasibility of a 3D quantification of the fixation of thyroid residues in a VERITON-CT™ camera |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Véronique ROCH, MSc | Contact | 0383154276 | +33 | v.roch@chru-nancy.fr |
| Name | Affiliation | Role |
|---|---|---|
| Elodie CHEVALIER, MD | CHRU Nancy | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chru Nancy Brabois | Recruiting | Vandœuvre-lès-Nancy | 54511 | France |
Not provided
| ID | Term |
|---|---|
| D013964 | Thyroid Neoplasms |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006258 | Head and Neck Neoplasms |
Not provided
Not provided
Patients received Iode 131 for thyroid cancer and 72 hours after taking iodine capsule,
Not provided
Not provided
Not provided
Not provided
Measurement of absolute quantification with the 2 procedures
| 18 months |
| Evaluate the two exams in terms of ergonomics for technologists | Likert scale results | 18 months |
| D004700 |
| Endocrine System Diseases |
| D013959 | Thyroid Diseases |